A Phase III, Randomized, Multicenter, Parallel-Group, Non-Inferiority
Research payments
$6,631,627
Through program year 2023, $6,631,627 in research payments was reported against A Phase III, Randomized, Multicenter, Parallel-Group, Non-Inferiority, across 1,472 payments, paid by ViiV Healthcare Company.
- Paid by
- ViiV Healthcare Company
- ClinicalTrials.gov
- No trial number was reported for this study
By program year
5 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2023 | Research | $174,563 | 40 |
| 2022 | Research | $1,925,024 | 373 |
| 2021 | Research | $1,472,015 | 349 |
| 2020 | Research | $1,239,849 | 317 |
| 2019 | Research | $1,820,177 | 393 |
Breakdown
Usually the institution or organisation running the study, not a person.
Records
Every payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
Principal investigators named
9 shownNamed on the study's payments. Being named is not being paid: the money in the figures above went to the recipients listed, not necessarily to these people.
- Michael Wohlfeiler Miami Beach, FL Named on 49 payments
- David Stein Bronx, NY Named on 29 payments
- Ogechika Alozie El Paso, TX Named on 29 payments
- Jorge Rodriguez Los Angeles, CA Named on 29 payments
- Anthony Mills Los Angeles, CA Named on 25 payments
- Olayemi Osiyemi West Palm Beach, FL Named on 25 payments
- Paul Benson Berkley, MI Named on 23 payments
- Peter Ruane Los Angeles, CA Named on 20 payments
- Gary Simon Washington, DC Named on 18 payments
What you are looking at
Research payments are tied to a study. Being named on a study as a principal investigator is reported separately from being paid as a recipient, and the two are not the same thing — a named investigator has not necessarily received the money.